{
    "root": "3415dbb0-48df-05e5-e063-6294a90a7516",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Citalopram",
    "value": "20250501",
    "ingredients": [
        {
            "name": "CITALOPRAM HYDROBROMIDE",
            "code": "I1E9D14F36"
        }
    ],
    "indications": "citalopram tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
    "contraindications": "• administer daily without food ( 2 ) . • initial 20 mg daily ; one week may increase maximum 40 mg daily ( 2.1 ) . • patients greater 60 years age , patients hepatic impairment , cyp2c19 poor metabolizers : maximum recommended 20 mg daily ( 2.2 ) . • discontinuing citalopram tablets , reduce gradually ( 2.4 , 5.6 ) .",
    "warningsAndPrecautions": "citalopram tablets , usp contain citalopram hydrobromide usp , equivalent 20 mg citalopram base . citalopram tablets , usp 20 mg , tan coloured , oval shaped , biconvex film coated tablets ‘ 2│0 ’ debossed ( ‘ 2 ’ left side ‘ 0 ’ right side break line ) one side ‘ 1010 ’ side . ndc : 70518-4335-00 packaging : 30 1 blister pack store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "citalopram tablets contraindicated patients : • taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . • taking pimozide risk qt prolongation [ ( 7 ) ] . • known hypersensitivity citalopram inactive ingredients citalopram tablets . included angioedema anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see Clinical Studies (\n  \n   14)]\n \n  .",
    "contraindications_original": "• Administer once daily with or without food ( 2 ) . • Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily ( 2.1 ) . • Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily ( 2.2 ) . • When discontinuing citalopram tablets, reduce dosage gradually ( 2.4 , 5.6 ) .",
    "warningsAndPrecautions_original": "Citalopram Tablets, USP contain citalopram hydrobromide USP, equivalent to 20 mg citalopram base.\n                  Citalopram Tablets, USP 20 mg, Tan coloured, oval shaped, biconvex film coated tablets with ‘2│0’ debossed (‘2’ on left side and ‘0’ on right side of the break line) on one side and ‘1010’ on the other side.\n                  \n                  NDC: 70518-4335-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Citalopram tablets are contraindicated in patients: \n    • taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome\n \n  [see Warnings and Precautions (\n  \n   5.3), Drug Interactions (\n  \n   7)]\n \n  . \n    • taking pimozide because of risk of QT prolongation\n \n  [see Drug Interactions (\n  \n   7)]\n \n  . \n    • with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. Reactions have included angioedema and anaphylaxis\n \n  [see Adverse Reactions (\n  \n   6.2)]\n \n  ."
}